Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemia
Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemia
Knowledge of the genomic landscape of chronic lymphocytic leukemia (CLL) grows increasingly detailed, providing challenges in contextualizing the accumulated information. To define the underlying networks, we here perform a multi-platform molecular characterization. We identify major subgroups characterized by genomic instability (GI) or activation of epithelial-mesenchymal-transition (EMT)-like programs, which subdivide into non-inflammatory and inflammatory subtypes. GI CLL exhibit disruption of genome integrity, DNA-damage response and are associated with mutagenesis mediated through activation-induced cytidine deaminase or defective mismatch repair. TP53 wild-type and mutated/deleted cases constitute a transcriptionally uniform entity in GI CLL and show similarly poor progression-free survival at relapse. EMT-like CLL exhibit high genomic stability, reduced benefit from the addition of rituximab and EMT-like differentiation is inhibited by induction of DNA damage. This work extends the perspective on CLL biology and risk categories in TP53 wild-type CLL. Furthermore, molecular targets identified within each subgroup provide opportunities for new treatment approaches.
Cragg, Mark
ec97f80e-f3c8-49b7-a960-20dff648b78c
Bloehdorn, Johannes
2a137cf4-cbbf-4a71-97e0-ff42e6a03ed8
Braun, Andrejs
a40f851b-1cd7-4ce7-8c25-832e38950f52
Taylor-Weiner, Amaro
bdc3d77f-47da-4358-8b98-ac75469e941e
Chelliah Jebaraj, Billy Michael
033b0d8a-d8a9-4c72-bc55-d32b7d29bcb2
Robrecht, Sandra
9bb754ff-e49a-4a5c-be50-5d149057c92f
Krzykalla, Julia
2d7a86e4-b2c9-4733-8624-2a08f764c3bc
Pan, Heng
329943be-bc3f-4be0-983b-4a604e499a22
Giza, Adam
36f36415-0818-4703-93ab-284de56858fd
Akylzhanova, Gulnara
c5e6e9eb-6088-4ff7-99da-22ef27389daa
Holzmann, Karlheinz
f6b5d2aa-e5a1-42d6-8deb-ba095d98d767
Scheffold, Annika
8359216d-39a1-43d1-be80-054be518013e
Johnston, Harvey E.
3c4b1bf2-a8c2-4bc3-bce7-179a379b107a
Yeh, Ru-Fang
62783233-cf36-45d2-82bf-3e02141b79b4
Klymenko, Tetyana
425ffc10-cad7-4490-b64f-b036651a4ca2
Eichorst, Barbara
b2acfde0-941a-4608-964c-ad44f9008582
Bullinger, Lars
5a395588-dc36-4850-bd2c-5f66a0ca643b
Fischer, Kirsten
9e9e7f35-d0ca-4083-893c-787e5604b9f5
Weisser, Martin Weisser
9a4d5a70-67f6-4d1d-8a88-fec1974c01b0
Robak, Tadeusz
6af9dae2-63f7-4662-ae14-b3ed21d9f9fd
Schneider, Christof
74bd3329-c3af-4d1f-915d-286b226e2e3a
Gribben, John
44bc1786-1a6f-4b18-b73a-b7486655e20b
Dahal, Lekh N
1e993a7a-b007-4187-82ea-e28dd3920b66
Carter, Matthew J.
4be5417e-2d76-4be6-bcf8-b0b9f00993be
Elemento, Oliver
b0b52c31-0390-45d2-89a2-d7ccb2bb46ef
Landau, Dan A.
44121296-9614-4e45-bafe-ead30a5aaa70
Neuberg, Donna S.
15d3d4d0-f10c-4400-9bb5-c2225878aa83
Cragg, Mark S.
3f4b0eb1-c051-481b-8581-bbd45994261d
Benner, Axel
49c62844-faff-433c-83fa-98d8a41571df
Hallek, Michael
a89a1dba-2fe4-4361-898e-3189e113417d
Wu, Catherine J
ccfe9fd3-5487-4b67-a02c-6e34ae3d39a4
Dohner, Hartmut
4abd8398-69e6-427a-8987-8345f825ef34
Stilgenbauer, Stephan
387838fa-a946-4293-83a1-734e08294f61
Mertens, Daniel
633b1185-e299-4565-ac45-3a4e50e6c1f4
13 September 2021
Cragg, Mark
ec97f80e-f3c8-49b7-a960-20dff648b78c
Bloehdorn, Johannes
2a137cf4-cbbf-4a71-97e0-ff42e6a03ed8
Braun, Andrejs
a40f851b-1cd7-4ce7-8c25-832e38950f52
Taylor-Weiner, Amaro
bdc3d77f-47da-4358-8b98-ac75469e941e
Chelliah Jebaraj, Billy Michael
033b0d8a-d8a9-4c72-bc55-d32b7d29bcb2
Robrecht, Sandra
9bb754ff-e49a-4a5c-be50-5d149057c92f
Krzykalla, Julia
2d7a86e4-b2c9-4733-8624-2a08f764c3bc
Pan, Heng
329943be-bc3f-4be0-983b-4a604e499a22
Giza, Adam
36f36415-0818-4703-93ab-284de56858fd
Akylzhanova, Gulnara
c5e6e9eb-6088-4ff7-99da-22ef27389daa
Holzmann, Karlheinz
f6b5d2aa-e5a1-42d6-8deb-ba095d98d767
Scheffold, Annika
8359216d-39a1-43d1-be80-054be518013e
Johnston, Harvey E.
3c4b1bf2-a8c2-4bc3-bce7-179a379b107a
Yeh, Ru-Fang
62783233-cf36-45d2-82bf-3e02141b79b4
Klymenko, Tetyana
425ffc10-cad7-4490-b64f-b036651a4ca2
Eichorst, Barbara
b2acfde0-941a-4608-964c-ad44f9008582
Bullinger, Lars
5a395588-dc36-4850-bd2c-5f66a0ca643b
Fischer, Kirsten
9e9e7f35-d0ca-4083-893c-787e5604b9f5
Weisser, Martin Weisser
9a4d5a70-67f6-4d1d-8a88-fec1974c01b0
Robak, Tadeusz
6af9dae2-63f7-4662-ae14-b3ed21d9f9fd
Schneider, Christof
74bd3329-c3af-4d1f-915d-286b226e2e3a
Gribben, John
44bc1786-1a6f-4b18-b73a-b7486655e20b
Dahal, Lekh N
1e993a7a-b007-4187-82ea-e28dd3920b66
Carter, Matthew J.
4be5417e-2d76-4be6-bcf8-b0b9f00993be
Elemento, Oliver
b0b52c31-0390-45d2-89a2-d7ccb2bb46ef
Landau, Dan A.
44121296-9614-4e45-bafe-ead30a5aaa70
Neuberg, Donna S.
15d3d4d0-f10c-4400-9bb5-c2225878aa83
Cragg, Mark S.
3f4b0eb1-c051-481b-8581-bbd45994261d
Benner, Axel
49c62844-faff-433c-83fa-98d8a41571df
Hallek, Michael
a89a1dba-2fe4-4361-898e-3189e113417d
Wu, Catherine J
ccfe9fd3-5487-4b67-a02c-6e34ae3d39a4
Dohner, Hartmut
4abd8398-69e6-427a-8987-8345f825ef34
Stilgenbauer, Stephan
387838fa-a946-4293-83a1-734e08294f61
Mertens, Daniel
633b1185-e299-4565-ac45-3a4e50e6c1f4
Cragg, Mark, Bloehdorn, Johannes, Braun, Andrejs, Taylor-Weiner, Amaro, Chelliah Jebaraj, Billy Michael, Robrecht, Sandra, Krzykalla, Julia, Pan, Heng, Giza, Adam, Akylzhanova, Gulnara, Holzmann, Karlheinz, Scheffold, Annika, Johnston, Harvey E., Yeh, Ru-Fang, Klymenko, Tetyana, Eichorst, Barbara, Bullinger, Lars, Fischer, Kirsten, Weisser, Martin Weisser, Robak, Tadeusz, Schneider, Christof, Gribben, John, Dahal, Lekh N, Carter, Matthew J., Elemento, Oliver, Landau, Dan A., Neuberg, Donna S., Cragg, Mark S., Benner, Axel, Hallek, Michael, Wu, Catherine J, Dohner, Hartmut, Stilgenbauer, Stephan and Mertens, Daniel
(2021)
Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemia.
Nature Communications, 12 (1), [5395].
(doi:10.1038/s41467-021-25403-y).
Abstract
Knowledge of the genomic landscape of chronic lymphocytic leukemia (CLL) grows increasingly detailed, providing challenges in contextualizing the accumulated information. To define the underlying networks, we here perform a multi-platform molecular characterization. We identify major subgroups characterized by genomic instability (GI) or activation of epithelial-mesenchymal-transition (EMT)-like programs, which subdivide into non-inflammatory and inflammatory subtypes. GI CLL exhibit disruption of genome integrity, DNA-damage response and are associated with mutagenesis mediated through activation-induced cytidine deaminase or defective mismatch repair. TP53 wild-type and mutated/deleted cases constitute a transcriptionally uniform entity in GI CLL and show similarly poor progression-free survival at relapse. EMT-like CLL exhibit high genomic stability, reduced benefit from the addition of rituximab and EMT-like differentiation is inhibited by induction of DNA damage. This work extends the perspective on CLL biology and risk categories in TP53 wild-type CLL. Furthermore, molecular targets identified within each subgroup provide opportunities for new treatment approaches.
Text
Deciphering pathogenic networks in CLL - Nat.Com. 04_2021acc
- Accepted Manuscript
More information
Accepted/In Press date: 3 August 2021
Published date: 13 September 2021
Additional Information:
Funding Information:
S.S. received advisory board honoraria, research support, travel support, speaker fees from AbbVie, Amgen, AstraZeneca, Celgene, Gilead, GSK, Hoffmann-La Roche, Janssen, Novartis, Sunesis. O.E. is supported by Janssen, Johnson and Johnson, Volastra Therapeutics, AstraZeneca, and Eli Lilly research grants. He is a scientific advisor and equity holder in Freenome, Owkin, Volastra Therapeutics and One Three Biotech and paid scientific advisor to Champion Oncology. M.S.C. is a retained consultant for BioInvent International and has performed educational and advisory roles for Roche, Boehringer Ingelheim, Baxalta, Merck KGaA, and GLG. He has received research funding from Bioinvent, Roche, Gilead, iTeos, UCB, and GSK. He is co-inventor of patent WO2012022985A1 protecting antibodies directed to hFcgRIIB in combination with CD20 specific antibodies. L.B.: Advisory Committees Abbvie, Amgen, Astellas, Bristol-Myers Squibb, Celgene, Daiichi Sankyo, Gilead, Hexal, Janssen, Jazz Pharmaceuticals, Menarini, Novartis, Pfizer, Sanofi, Seattle Genetics. R-F.Y. and M.W. are employed by Genentech and Roche, respectively. J.B. received travel support from Janssen and research support from Roche. The remaining authors declare no competing interests.
Funding Information:
The authors thank all patients and their physicians for trial participation and donation of samples; the DCLLSG; Sabrina Schrell and Christina Galler for their excellent technical assistance. This work was supported by research grants from the Else Kröner-Fresenius-Stiftung (2010_Kolleg24, 2012_A146), BMBF (PRECISE), Cancer Research UK (A24721 and A18087), Kay Kendall Leukemia Fund (KKL1101), and Blood Cancer UK (19001), European Commission/BMBF (“FIRE CLL”, 01KT160), SFB 1074 (Projects B1, B2), DJCLS R 11/01.
Publisher Copyright:
© 2021, The Author(s).
Identifiers
Local EPrints ID: 451904
URI: http://eprints.soton.ac.uk/id/eprint/451904
ISSN: 2041-1723
PURE UUID: 1387cdff-71f8-468b-aefb-fd7636ad4504
Catalogue record
Date deposited: 03 Nov 2021 17:30
Last modified: 06 Jun 2024 01:36
Export record
Altmetrics
Contributors
Author:
Johannes Bloehdorn
Author:
Andrejs Braun
Author:
Amaro Taylor-Weiner
Author:
Billy Michael Chelliah Jebaraj
Author:
Sandra Robrecht
Author:
Julia Krzykalla
Author:
Heng Pan
Author:
Adam Giza
Author:
Gulnara Akylzhanova
Author:
Karlheinz Holzmann
Author:
Annika Scheffold
Author:
Harvey E. Johnston
Author:
Ru-Fang Yeh
Author:
Tetyana Klymenko
Author:
Barbara Eichorst
Author:
Lars Bullinger
Author:
Kirsten Fischer
Author:
Martin Weisser Weisser
Author:
Tadeusz Robak
Author:
Christof Schneider
Author:
John Gribben
Author:
Lekh N Dahal
Author:
Matthew J. Carter
Author:
Oliver Elemento
Author:
Dan A. Landau
Author:
Donna S. Neuberg
Author:
Mark S. Cragg
Author:
Axel Benner
Author:
Michael Hallek
Author:
Catherine J Wu
Author:
Hartmut Dohner
Author:
Stephan Stilgenbauer
Author:
Daniel Mertens
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
